Pharmacophore based virtual screening, molecular docking studies to design potent heat shock protein 90 inhibitors.

The identification of important chemical features of Heat Shock Protein 90 (HSP90) inhibitors will be helpful to discover the potent candidate to inhibit the HSP90 activity. The best hypothesis from Hip-Hop, Hypo1, one hydrogen bond donor (HBD), two hydrogen bond acceptors (HBA), and two hydrophobic (H) and structure-based hypothesis, SB_Hypo1, one HBA, one HBD and four H features, were generated using Discovery Studio and LigandScout, respectively. Test and decoy sets were used to corroborate the best hypotheses and the validated hypotheses were used to screen the chemical databases. Subsequently, the screened compounds were filtered by applying the rule of five, ADMET and molecular docking. Finally, four compounds were obtained as novel leads to inhibit the HSP90 activity.

[1]  Xavier Barril,et al.  Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. , 2005, Journal of medicinal chemistry.

[2]  Paulien Hogeweg,et al.  Evolutionary Dynamics and the Coding Structure of Sequences: Multiple Coding as a Consequence of Crossover and High Mutation Rates , 1992, Comput. Chem..

[3]  Sugunadevi Sakkiah,et al.  3D QSAR pharmacophore based virtual screening and molecular docking for identification of potential HSP90 inhibitors. , 2010, European journal of medicinal chemistry.

[4]  L. Funk,et al.  Dihydroxylphenyl amides as inhibitors of the Hsp90 molecular chaperone. , 2008, Bioorganic & medicinal chemistry letters.

[5]  D. Solit,et al.  Hsp90: the vulnerable chaperone. , 2004, Drug discovery today.

[6]  J. Caldwell,et al.  Crystal structures of human HSP90α-complexed with dihydroxyphenylpyrazoles , 2005 .

[7]  M. Adler,et al.  Potent Triazolothione Inhibitor of Heat‐Shock Protein‐90 , 2009, Chemical biology & drug design.

[8]  L. Whitesell,et al.  Altered Hsp90 function in cancer: a unique therapeutic opportunity. , 2004, Molecular cancer therapeutics.

[9]  R. Nilakantan,et al.  Discovery of benzisoxazoles as potent inhibitors of chaperone heat shock protein 90. , 2008, Journal of medicinal chemistry.

[10]  M. Letizia Barreca,et al.  Structure-Based Pharmacophore Identification of New Chemical Scaffolds as Non-Nucleoside Reverse Transcriptase Inhibitors , 2007, J. Chem. Inf. Model..

[11]  Giulio Rastelli,et al.  Structure‐Based and in silico Design of Hsp90 Inhibitors , 2009, ChemMedChem.

[12]  Jean M. Severin,et al.  Discovery and Design of Novel HSP90 Inhibitors Using Multiple Fragment‐based Design Strategies , 2007, Chemical biology & drug design.

[13]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[14]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[15]  Matthew P. Repasky,et al.  Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. , 2004, Journal of medicinal chemistry.

[16]  Gabriela Chiosis,et al.  Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. , 2006, Journal of medicinal chemistry.

[17]  F. Storlie.  Henry , 1978, The American journal of nursing.

[18]  D. Taub,et al.  Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers , 2004, Cancer biology & therapy.

[19]  Neal Rosen,et al.  Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent , 1997, Cell.

[20]  J M Thornton,et al.  LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.

[21]  3-(5-Chloro-2,4-dihydroxyphenyl)-pyrazole-4-carboxamides as inhibitors of the Hsp90 molecular chaperone. , 2005, Bioorganic & medicinal chemistry letters.

[22]  D. Solit,et al.  Development and application of Hsp90 inhibitors. , 2008, Drug discovery today.

[23]  Mark Whittaker,et al.  Fragment‐based Identification of Hsp90 Inhibitors , 2009, ChemMedChem.

[24]  Ingo Muegge,et al.  Advances in virtual screening , 2006, Drug Discovery Today: Technologies.

[25]  L. Pearl,et al.  Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues , 2007, Molecular Cancer Therapeutics.

[26]  P. Workman.  Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone. , 2002, Cancer detection and prevention.

[27]  M. Egorin,et al.  Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. , 1998, Cancer research.

[28]  M. Minami,et al.  Constantly updated knowledge of Hsp90. , 2005, Journal of biochemistry.

[29]  X. Barril,et al.  A fluorescence polarization assay for inhibitors of Hsp90. , 2006, Analytical biochemistry.

[30]  Mike Wood,et al.  4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. , 2007, Journal of medicinal chemistry.

[31]  D. Joseph-McCarthy,et al.  Automated generation of MCSS‐derived pharmacophoric DOCK site points for searching multiconformation databases , 2003, Proteins.

[32]  Evan Bolton,et al.  An overview of the PubChem BioAssay resource , 2009, Nucleic Acids Res..

[33]  Giulio Rastelli,et al.  Crystal structure and molecular modeling of 17-DMAG in complex with human Hsp90. , 2003, Chemistry & biology.

[34]  R. Kuchta,et al.  Role of the 2-amino group of purines during dNTP polymerization by human DNA polymerase alpha. , 2009, Biochemistry.

[35]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[36]  Tao Zhang,et al.  New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[37]  A. Ben Wagner,et al.  SciFinder Scholar 2006: An Empirical Analysis of Research Topic Query Processing , 2006, J. Chem. Inf. Model..

[38]  Andrew Smellie,et al.  Poling: Promoting conformational variation , 1995, J. Comput. Chem..

[39]  X. Barril,et al.  Structure-based discovery of a new class of Hsp90 inhibitors. , 2005, Bioorganic & medicinal chemistry letters.

[40]  R. Glen,et al.  Molecular recognition of receptor sites using a genetic algorithm with a description of desolvation. , 1995, Journal of molecular biology.

[41]  L. Petrucelli,et al.  Development of a high throughput drug screening assay for the detection of changes in tau levels -- proof of concept with HSP90 inhibitors. , 2005, Current Alzheimer research.

[42]  X. Barril,et al.  Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. , 2004, Chemistry & biology.

[43]  F. Young.  Biochemistry , 1955, The Indian Medical Gazette.

[44]  Jason C. Young,et al.  The heat shock protein 90-targeting drug cisplatin selectively inhibits steroid receptor activation. , 2003, Molecular endocrinology.

[45]  C. Venkatachalam,et al.  LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites. , 2003, Journal of molecular graphics & modelling.

[46]  A. Minelli.  BIO , 2009, Evolution & Development.

[47]  Xavier Barril,et al.  4-Amino derivatives of the Hsp90 inhibitor CCT018159. , 2006, Bioorganic & medicinal chemistry letters.

[48]  M. Congreve,et al.  Recent developments in fragment-based drug discovery. , 2008, Journal of medicinal chemistry.

[49]  P. Csermely,et al.  Hsp90 isoforms: functions, expression and clinical importance , 2004, FEBS letters.

[50]  Hege S. Beard,et al.  Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. , 2004, Journal of medicinal chemistry.

[51]  Thierry Langer,et al.  LigandScout: 3-D Pharmacophores Derived from Protein-Bound Ligands and Their Use as Virtual Screening Filters , 2005, J. Chem. Inf. Model..

[52]  Ming-Li Xiang,et al.  Pharmacophore Modelling and Virtual Screening for Identification of New Aurora‐A Kinase Inhibitors , 2008, Chemical biology & drug design.

[53]  M. Saraste,et al.  FEBS Lett , 2000 .

[54]  J. Veal,et al.  Discovery of benzamide tetrahydro-4H-carbazol-4-ones as novel small molecule inhibitors of Hsp90. , 2008, Bioorganic & medicinal chemistry letters.

[55]  M. Amolins,et al.  Natural product inhibitors of Hsp90: potential leads for drug discovery. , 2009, Mini reviews in medicinal chemistry.

[56]  G. Klebe.  Virtual ligand screening: strategies, perspectives and limitations , 2006, Drug Discovery Today.